Nektar Therapeutics Class Action Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NKTR?
Source: PRnewswire
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action.
- Fee Arrangement: Investors participating in the Nektar class action will not incur any out-of-pocket costs, as the law firm will operate on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that the defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated trial integrity and resulting in investor losses once the true details were disclosed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its strong capabilities in this field.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 100.350
Low
102.00
Averages
123.43
High
165.00
Current: 100.350
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nektar Therapeutics Prices $325 Million Upsized Public Offering
- Upsized Offering: Nektar Therapeutics announced the pricing of an upsized public offering of 3,532,609 shares at $92.00 per share, expected to generate approximately $325 million, providing substantial funding for its research and clinical trials.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated for general corporate purposes, including supporting Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata, reflecting the company's commitment to its lead product and confidence in its market potential.
- Strong Underwriting Team: The offering is managed by a robust team including Jefferies, TD Cowen, and Piper Sandler, with Citigroup also participating, which is expected to enhance market confidence in the offering's success.
- Regulatory Compliance: This offering is conducted under an effective S-3ASR registration statement, ensuring compliance and transparency, with an expected closing date of April 23, 2026, further bolstering investor trust in Nektar.
See More
Nektar Therapeutics Prices Upsized $325M Public Offering
- Upsized Offering: Nektar Therapeutics has announced an increase in its public offering from an initially proposed $250 million to $325 million, indicating strong market demand and expected significant funding support for the company.
- Offering Details: The company is selling 3.53 million shares at a price of $92.00 per share, with gross proceeds expected to be around $325 million before fees and expenses, which will be allocated for general corporate purposes including R&D and clinical development.
- Underwriter Option: Nektar has granted underwriters a 30-day option to purchase an additional 529,891 shares at the same price, further enhancing investor interest in the stock.
- Use of Proceeds: The net proceeds are planned to be used for research and manufacturing costs, including Phase 3 trials for rezpegaldesleukin, which will help advance its drug candidates and strengthen future market competitiveness.
See More
Nektar Therapeutics Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action.
- Fee Arrangement: Investors participating in the Nektar class action will not incur any out-of-pocket costs, as the law firm will operate on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that the defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated trial integrity and resulting in investor losses once the true details were disclosed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its strong capabilities in this field.
See More
Nektar Therapeutics Prices $325 Million Upsized Public Offering
- Upsized Offering: Nektar Therapeutics announced the pricing of 3,532,609 shares at $92.00 each, raising approximately $325 million, reflecting strong market confidence in its immunotherapy products.
- Clear Use of Proceeds: The net proceeds will be allocated for general corporate purposes, including research and development, clinical trials (notably Phase 3 for atopic dermatitis and alopecia areata), and manufacturing costs, aimed at accelerating the advancement of its drug candidates.
- Strong Underwriter Support: Jefferies, TD Cowen, and Piper Sandler are acting as joint bookrunning managers for the offering, with Citigroup also participating, indicating robust investment banking support and market recognition for Nektar.
- Regulatory Compliance: The offering is made under an effective S-3ASR registration statement, ensuring compliance and streamlining the issuance process, with an expected closing date of April 23, 2026, enhancing the company's transparency in capital markets.
See More
Nektar Therapeutics Class Action Notice Issued
- Class Action Deadline: Purchasers of Nektar Therapeutics securities from February 26, 2025, to December 15, 2025, must be aware that the lead plaintiff deadline is May 5, 2026, after which they cannot participate in claims.
- Transparent Fee Structure: Participants can obtain compensation through a contingency fee arrangement without upfront costs, ensuring that investors do not bear additional financial burdens during the legal process, thereby lowering the barriers to participation.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong capabilities and successful track record, which enhances investor confidence.
- Core Allegations: The lawsuit alleges that Nektar failed to follow applicable instructions and protocol standards in the REZOLVE-AA trial, raising concerns about the integrity of the trial results, which could lead to investor losses, highlighting the importance of corporate transparency and compliance.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: A class action lawsuit against Boston Scientific Corporation (NYSE:BSX) alleges that from July 23, 2025, to February 3, 2026, the company failed to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, which severely undermined investor confidence and is expected to negatively impact stock performance.
- Eos Energy Issues: Eos Energy Enterprises (NASDAQ:EOSE) faces a class action lawsuit for the period from November 5, 2025, to February 26, 2026, alleging that the company could not achieve necessary production ramp-up and that its battery line downtime exceeded industry norms, potentially leading to a decline in market share and investor trust.
- Soleno Therapeutics Risks: Soleno Therapeutics, Inc. (NASDAQ:SLNO) is accused in a class action lawsuit covering March 26, 2025, to November 4, 2025, of concealing significant safety concerns related to its DCCR clinical trial, which could materially affect its commercial viability and expose investors to legal and reputational risks.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics (NASDAQ:NKTR) is implicated in a class action lawsuit for the period from February 26, 2025, to December 15, 2025, for failing to adhere to trial protocols in its REZOLVE-AA trial, likely compromising the trial's integrity and further eroding investor confidence in the company's future prospects.
See More
Nektar Therapeutics Prices $325 Million Upsized Public Offering
- Upsized Offering: Nektar Therapeutics announced the pricing of an upsized public offering of 3,532,609 shares at $92.00 per share, expected to generate approximately $325 million, providing substantial funding for its research and clinical trials.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated for general corporate purposes, including supporting Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata, reflecting the company's commitment to its lead product and confidence in its market potential.
- Strong Underwriting Team: The offering is managed by a robust team including Jefferies, TD Cowen, and Piper Sandler, with Citigroup also participating, which is expected to enhance market confidence in the offering's success.
- Regulatory Compliance: This offering is conducted under an effective S-3ASR registration statement, ensuring compliance and transparency, with an expected closing date of April 23, 2026, further bolstering investor trust in Nektar.
See More
Nektar Therapeutics Prices Upsized $325M Public Offering
- Upsized Offering: Nektar Therapeutics has announced an increase in its public offering from an initially proposed $250 million to $325 million, indicating strong market demand and expected significant funding support for the company.
- Offering Details: The company is selling 3.53 million shares at a price of $92.00 per share, with gross proceeds expected to be around $325 million before fees and expenses, which will be allocated for general corporate purposes including R&D and clinical development.
- Underwriter Option: Nektar has granted underwriters a 30-day option to purchase an additional 529,891 shares at the same price, further enhancing investor interest in the stock.
- Use of Proceeds: The net proceeds are planned to be used for research and manufacturing costs, including Phase 3 trials for rezpegaldesleukin, which will help advance its drug candidates and strengthen future market competitiveness.
See More
Nektar Therapeutics Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to represent other investors in the class action.
- Fee Arrangement: Investors participating in the Nektar class action will not incur any out-of-pocket costs, as the law firm will operate on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that the defendants failed to adhere to applicable instructions and protocol standards in the REZOLVE-AA trial, leading to overstated trial integrity and resulting in investor losses once the true details were disclosed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and recovered over $438 million for investors in 2019 alone, being ranked first in 2017 for the number of securities class action settlements, showcasing its strong capabilities in this field.
See More
Nektar Therapeutics Prices $325 Million Upsized Public Offering
- Upsized Offering: Nektar Therapeutics announced the pricing of 3,532,609 shares at $92.00 each, raising approximately $325 million, reflecting strong market confidence in its immunotherapy products.
- Clear Use of Proceeds: The net proceeds will be allocated for general corporate purposes, including research and development, clinical trials (notably Phase 3 for atopic dermatitis and alopecia areata), and manufacturing costs, aimed at accelerating the advancement of its drug candidates.
- Strong Underwriter Support: Jefferies, TD Cowen, and Piper Sandler are acting as joint bookrunning managers for the offering, with Citigroup also participating, indicating robust investment banking support and market recognition for Nektar.
- Regulatory Compliance: The offering is made under an effective S-3ASR registration statement, ensuring compliance and streamlining the issuance process, with an expected closing date of April 23, 2026, enhancing the company's transparency in capital markets.
See More
Nektar Therapeutics Class Action Notice Issued
- Class Action Deadline: Purchasers of Nektar Therapeutics securities from February 26, 2025, to December 15, 2025, must be aware that the lead plaintiff deadline is May 5, 2026, after which they cannot participate in claims.
- Transparent Fee Structure: Participants can obtain compensation through a contingency fee arrangement without upfront costs, ensuring that investors do not bear additional financial burdens during the legal process, thereby lowering the barriers to participation.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong capabilities and successful track record, which enhances investor confidence.
- Core Allegations: The lawsuit alleges that Nektar failed to follow applicable instructions and protocol standards in the REZOLVE-AA trial, raising concerns about the integrity of the trial results, which could lead to investor losses, highlighting the importance of corporate transparency and compliance.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: A class action lawsuit against Boston Scientific Corporation (NYSE:BSX) alleges that from July 23, 2025, to February 3, 2026, the company failed to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, which severely undermined investor confidence and is expected to negatively impact stock performance.
- Eos Energy Issues: Eos Energy Enterprises (NASDAQ:EOSE) faces a class action lawsuit for the period from November 5, 2025, to February 26, 2026, alleging that the company could not achieve necessary production ramp-up and that its battery line downtime exceeded industry norms, potentially leading to a decline in market share and investor trust.
- Soleno Therapeutics Risks: Soleno Therapeutics, Inc. (NASDAQ:SLNO) is accused in a class action lawsuit covering March 26, 2025, to November 4, 2025, of concealing significant safety concerns related to its DCCR clinical trial, which could materially affect its commercial viability and expose investors to legal and reputational risks.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics (NASDAQ:NKTR) is implicated in a class action lawsuit for the period from February 26, 2025, to December 15, 2025, for failing to adhere to trial protocols in its REZOLVE-AA trial, likely compromising the trial's integrity and further eroding investor confidence in the company's future prospects.
See More
